A/Prof Emma Link
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
89 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
DOI: 10.1016/S1470-2045(26)00120-82026
Journal article
The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
DOI: 10.1002/bcp.704312026
Journal article
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
DOI: 10.1016/j.euo.2024.11.0062026
Journal article
Abstract GS2-12: Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): final 10-year analysis of a randomised, factorial, multicentre, open-label, phase 3 study
DOI: 10.1158/1557-3265.sabcs25-gs2-122025
Other
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
DOI: 10.1158/1078-0432.307075642025
Journal article
The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
DOI: 10.1158/1078-0432.CCR-25-07052024
Research grants (ARC, NHMRC, MRFF)
Radiation Doses and Fractionation Schedules in Non-Low-Risk Ductal Carcinoma in Situ in the Breast (BIG 3\201307/Trog 07.01): A Randomised, Factorial, Multicentre, Open-Label, Phase 3 Study
RECENT SCHOLARLY WORKS
2025
Journal article
Node-positive carcinoma of the vulva treated with curative-intent radiotherapy
DOI: 10.1016/j.ijgc.2025.1019162024
Journal article
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
DOI: 10.1111/bju.161902024
Journal article
UNICAB: Cabozantinib in locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802)
DOI: 10.1200/JCO.2024.42.4_suppl.4282023
Journal article
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma
DOI: 10.1186/s13148-023-01427-7
RECENT PROJECTS
2024
Research grants (ARC, NHMRC, MRFF)
Radiation Doses and Fractionation Schedules in Non-Low-Risk Ductal Carcinoma in Situ in the Breast (BIG 3\201307/Trog 07.01): A Randomised, Factorial, Multicentre, Open-Label, Phase 3 Study
2016
Research Grant
A Randomised Phase Iii Study of Radiation Doses and Fractionation Schedules for Non-Low Risk Ductal Carcinoma in Situ of the Breasta Randomised Phase Iii Study of Radiation Doses and Fractionation Schedules for Non-Low Risk Ductal Carcinoma in Situ of the Breast